Omega-3 carboxylic acids (Epanova®): A review of its use in patients with severe hypertriglyceridemia

American Journal of Cardiovascular Drugs

Volumn 14, Issue 5, 2014, Pages 393-400

  Blair, Hannah A ^a   Dhillon, Sohita ^a  

^a Springer   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL ESTER; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; CARBOXYLIC ACID;

CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INTERACTION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; FOOD INTAKE; GASTROINTESTINAL DISEASE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID DIET; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CARBOXYLIC ACIDS; DRUG INTERACTIONS; HUMANS; HYPERTRIGLYCERIDEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIGLYCERIDES;

EID: 84907565375     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-014-0090-3     Document Type: Review

References (22)

1. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(9):2969-89.
2. National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106(25):3143-421.
3. World Health Organization. The top 10 causes of death. 2014. http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed 26 Aug 2014.
4. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292-333.
5. Kataoka Y, Uno K, Puri R, et al. Epanova and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy. Future Cardiol. 2013;9(2):177-86.
6. Skulas-Ray AC, West SG, Davidson MH, et al. Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin Pharmacother. 2008;9(7):1237-48.
7. Weintraub H. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. Atherosclerosis. 2013;230(2):381-9.
8. Bradberry JC, Hilleman DE. Overview of omega-3 fatty acid therapies. P T. 2013;38(11):681-91.
9. Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006;98(4A):27i-33i.
10. GlaxoSmithKline. Lovaza (omega-3 acid ethyl esters) capsules: US prescribing information. 2008. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/021654s041lbl.pdf. Accessed 21 Aug 2008.
11. Trygg Pharma. Omega-3 acid ethyl esters A (Omtryg): US prescribing information. 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/204977s000lbl.pdf. Accessed 21 Aug 2014.
12. Amarin Corporation. Vascepa (icosapent ethyl) capsules: US prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/202057s009lbl.pdf. Accessed 21 Aug 2014.
13. AstraZeneca Pharmaceuticals LP. Omega-3 free fatty acids (Epanova): US prescribing information. 2014. http://www1.astrazeneca-us.com/pi/epanova.pdf. Accessed 9 Sep 2014.
14. Davidson MH, Johnson J, Rooney MW, et al. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol. 2012;6(6):573-84.
15. Offman E, Marenco T, Ferber S, et al. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. Vasc Health Risk Manag. 2013;9(1):563-73.
16. Kebir S, Davidson M, Marenco T, et al. Multiple doses of EPA/DHA do not alter the pharmacokinetics of simvastatin or the antiplatelet effect of ASA [abstract no. PII-1]. Clin Pharmacol Ther. 2013;93(Suppl 1):S52-3.
17. Kastelein JJP, Maki KC, Susekov A, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014;8(1):94-106.
18. Kastelein JJP, Maki KC, Susekov A, et al. Management of severe hypertriglyceridemia with a novel omega-3 free-fatty acid formulation: subgroups in the EVOLVE trial [abstract no. 159 plus poster]. J Clin Lipidol. 2013;7(3):271-2.
19. Rader DJ, Dunbar RL, Maki KC, et al. Apolipoprotein C-III is significantly reduced by prescription omega-3 free fatty acids (Epanova) in patients with severe hypertriglyceridemia and changes correlate with increases in LDL-C: a sub-analysis of the EVOLVE trial [abstract no. 19030]. Circulation. 2012;126(21 Suppl).
20. Maki KC, Orloff DG, Nicholls SJ et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013;35(9):1400-11.e3.
21. Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23(2):151-2.
22. AstraZeneca. Outcomes study to assess STatin Residual risk reduction with EpaNova in hiGh CV risk patienTs with hypertriglyceridemia (STRENGTH) [ClinicalTrials.gov identifier NCT02104817] US National Institutes of Health, ClinicalTrials.gov. 2014. http://clinicaltrials.gov/show/NCT02104817. Accessed 21 Aug 2014.